Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-08-09
2011-08-09
Skelding, Zachary (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C530S388230
Reexamination Certificate
active
07993645
ABSTRACT:
A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
REFERENCES:
patent: 5859205 (1999-01-01), Adair et al.
patent: 6060284 (2000-05-01), Bazan
patent: 6479634 (2002-11-01), Bazan
patent: 6495667 (2002-12-01), Bazan
patent: 6610285 (2003-08-01), Hirata
patent: 6756481 (2004-06-01), Chirica et al.
patent: 6800460 (2004-10-01), Oppmann et al.
patent: 6835825 (2004-12-01), Bazan
patent: RE39015 (2006-03-01), Bazan et al.
patent: 7090847 (2006-08-01), Oppmann et al.
patent: 7183382 (2007-02-01), Oppmann et al.
patent: 7247711 (2007-07-01), Benson et al.
patent: 7252971 (2007-08-01), Benson et al.
patent: 7282204 (2007-10-01), Oft et al.
patent: 7491391 (2009-02-01), Benson et al.
patent: 2002/0042386 (2002-04-01), Rosen et al.
patent: 2003/0124617 (2003-07-01), Gram et al.
patent: 2003/0162261 (2003-08-01), Oppmann et al.
patent: 2004/0185506 (2004-09-01), Heavner
patent: 2004/0258686 (2004-12-01), Chirica et al.
patent: 2005/0049402 (2005-03-01), Babcook et al.
patent: 2005/0208052 (2005-09-01), Katsikis et al.
patent: 2005/0244874 (2005-11-01), Kastelein et al.
patent: 2007/0048315 (2007-03-01), Presta
patent: WO 99/05280 (1999-02-01), None
patent: WO 99/40195 (1999-08-01), None
patent: WO 00/09552 (2000-02-01), None
patent: WO 00/53631 (2000-09-01), None
patent: WO 00/70049 (2000-11-01), None
patent: WO 01/18051 (2001-03-01), None
patent: WO 01/85790 (2001-11-01), None
patent: WO 2004/042009 (2004-05-01), None
patent: WO 2004/058178 (2004-07-01), None
patent: WO 2004/071517 (2004-08-01), None
patent: WO 2004/081190 (2004-09-01), None
patent: WO 2004/101750 (2004-11-01), None
patent: WO 2005/108425 (2005-11-01), None
patent: WO 2007/024846 (2007-03-01), None
Oppmann, et al., “Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12,” Immunity, 13: 715-725 (2000).
Peter J. Barnes, “Cytokine-directed therapies for the treatment of chronic airway diseases,” Cytokine & Growth Factor Reviews 14 (2003): 511-522 (2003).
Trinchieri, et al., “The IL-12 Family of Heterodimeric Cytokines: New Players in the Regulation of T Cell Responses,” Immunity, 19: 641-644 (2003).
Maguire van Seventer, et al., “Interferon-β differentially regulates expression of the IL-12 family members p35, p40, p19 and EB13 in activated human dendritic cells,” Journal of Neuroimmunology, 133: 60-71 (2002).
Yadav, et al., “Cytokines and autoimmunity: redundancy defines their complex nature,” Current Opinion in Immunology, 15: 697-703 (2003).
Murphy, et al., “Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation,” Journal of Experimental Medicine, 198(12): 1951-1957 (2003).
David M. Frucht, “IL-23: A Cytokine That Acts on Memory T Cells,” Science STKE, 114: 1-3 (2002).
Wiekowski, et al., “Ubiquitous Transgenic Expression of the IL-23 Subunit p19 Induces Multiorgan Inflammation, Runting, Infertility, and Premature Death,” Journal of Immunology, 166: 7563-7570 (2001).
Belladonna, et al., “IL-23 and IL-12 Have Overlapping, but Distinct, Effects on Murine Dendritic Cells,” The Journal of Immunology, 168: 5448-5454 (2002).
Parham, et al., “A Receptor for the Heterodimeric Cytokine IL-23 is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R,” The Journal of Immunology, 168: 5699-5708 (2002).
Cua, et al., “Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain,” Nature, 421: 744-748 (2003).
GenBank Accession No. AF301620, Oppmann, et al., Dec. 4, 2000.
GenBank Accession No. AA418955, Hillier, et al., May 12, 1997.
GenBank Accession No. C06368, J. Takeda, Aug. 9, 1996.
GenBank Accession No. AA418747, Hillier, et al., May 12, 1997.
Wiendl, et al., “Therapeutic Approaches in Multiple Sclerosis: Lessons from Failed and Interrupted Treatment Trials,” BioDrugs, 16(3): 183-200 (2002).
Eduardo Padlan, “Anatomy of the Antibody Molecule,” Molecular Immunology, 31(3): 169-217 (1994).
Portolano, et al., “ Lack of Promiscuity in Autoantigen-Specific H and L Chain Combinations as Revealed by Human H and L Chain ‘Roulette’,” Journal of Immunology, 150(3): 880-887 (1993).
Knappik, et al., “Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides,” Journal of Molecular Biology, 296(1): 57-86 (2000).
Vajdos, et al., “Comprehensive Functional Maps of the Antigen-Binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” Journal of Molecular Biology, 320(2): 415-428 (2002).
PCT International Search Report dated Feb. 1, 2008.
Supplemental European Search Report dated Feb. 18, 2010.
Benson Jacqueline
Carton Jill
Cunningham Mark
Orlovsky Yevgeniya I.
Rauchenberger Robert
Dichter Eric
Janssen Biotech, Inc.
Skelding Zachary
LandOfFree
Human anti-IL-23 antibodies, compositions, methods and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human anti-IL-23 antibodies, compositions, methods and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human anti-IL-23 antibodies, compositions, methods and uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2658296